Roche Plays Down Reliance On TIGIT And Alzheimer’s Drugs For Growth

Company Boasts 51 Late-Stage Candidates

Pharma chief Bill Anderson was optimistic about growth prospects, and downplayed Roche’s reliance on two near-term readouts at an investor day in London.

Roche_Basel
Roche is banking on its sector-leading R&D expenditure to pay off over the next 5-10 years. • Source: Shutterstock

Roche has presented its vision for its pharma division up until 2025, outlining a wave of new molecules and growth opportunities across its portfolio, and highlighting potential first-in-class launches across oncology, neuroscience and ophthalmology.

The company is arguing that it can achieve strong growth in the period, even while accepting much reduced analysts' consensus...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip